These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 17369701)
21. Generated single point-mutations can considerably dismantle the lymphocyte overstimulation induced by Yersinia pseudotuberculosis superantigen. Seprényi G; Ito Y; Kohsaka T Cell Immunol; 1999 Mar; 192(2):96-106. PubMed ID: 10087177 [TBL] [Abstract][Full Text] [Related]
22. [Impact of Yersinia pseudotuberculosis on the in vitro production of cytokines by whole blood cells of donors]. Voropaev AV; Shurygina IA; Klimov VT; Chesnokova MV; Maramovich AS; Malov IV; Kirdeĭ EG Zh Mikrobiol Epidemiol Immunobiol; 2002; (4):48-51. PubMed ID: 12449699 [TBL] [Abstract][Full Text] [Related]
23. Purification and gene cloning of a superantigen (YPM) produced by a patient strain of Yersinia pseudotuberculosis. Takeda T; Yoshino K; Itoh Y; Abe J; Shimonishi Y; Kohsaka T Contrib Microbiol Immunol; 1995; 13():331-3. PubMed ID: 8833866 [No Abstract] [Full Text] [Related]
24. Crystallization and preliminary X-ray analysis of Yersinia pseudotuberculosis-derived mitogen. Donadini R; Wåhlberg M; Kohsaka T; Ito Y; Fields BA Acta Crystallogr D Biol Crystallogr; 2003 Jul; 59(Pt 7):1330-2. PubMed ID: 12832802 [TBL] [Abstract][Full Text] [Related]
25. Evidence for superantigen production by Yersinia pseudotuberculosis. Abe J; Takeda T; Watanabe Y; Nakao H; Kobayashi N; Leung DY; Kohsaka T J Immunol; 1993 Oct; 151(8):4183-8. PubMed ID: 8409395 [TBL] [Abstract][Full Text] [Related]
26. Conservation and variation in superantigen structure and activity highlighted by the three-dimensional structures of two new superantigens from Streptococcus pyogenes. Arcus VL; Proft T; Sigrell JA; Baker HM; Fraser JD; Baker EN J Mol Biol; 2000 May; 299(1):157-68. PubMed ID: 10860729 [TBL] [Abstract][Full Text] [Related]
27. Identification of a new type of invariant V alpha 14+ T cells and responsiveness to a superantigen, Yersinia pseudotuberculosis-derived mitogen. Yagi J; Dianzani U; Kato H; Okamoto T; Katsurada T; Buonfiglio D; Miyoshi-Akiyama T; Uchiyama T J Immunol; 1999 Sep; 163(6):3083-91. PubMed ID: 10477573 [TBL] [Abstract][Full Text] [Related]
28. Pathogenic role of a superantigen in Yersinia pseudotuberculosis infection. Abe J; Kano H; Nogami H; Matsumoto S; Baba K; Saito H; Kohsaka T Adv Exp Med Biol; 2003; 529():459-61. PubMed ID: 12756809 [No Abstract] [Full Text] [Related]
29. The complete genome sequence of Yersinia pseudotuberculosis IP31758, the causative agent of Far East scarlet-like fever. Eppinger M; Rosovitz MJ; Fricke WF; Rasko DA; Kokorina G; Fayolle C; Lindler LE; Carniel E; Ravel J PLoS Genet; 2007 Aug; 3(8):e142. PubMed ID: 17784789 [TBL] [Abstract][Full Text] [Related]
30. Characterization of a superantigen produced by Yersinia pseudotuberculosis. Abe J; Takeda T Prep Biochem Biotechnol; 1997; 27(2-3):173-208. PubMed ID: 9292925 [No Abstract] [Full Text] [Related]
31. Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: Yersinia pseudotuberculosis-Derived Mitogen A. Amphlett A Open Forum Infect Dis; 2016 Jan; 3(1):ofv202. PubMed ID: 26819960 [TBL] [Abstract][Full Text] [Related]
32. Structure of the Y. pseudotuberculosis adhesin InvasinE. Sadana P; Mönnich M; Unverzagt C; Scrima A Protein Sci; 2017 Jun; 26(6):1182-1195. PubMed ID: 28370712 [TBL] [Abstract][Full Text] [Related]
34. Analysis of functional regions of YPM, a superantigen derived from gram-negative bacteria. Ito Y; Seprényi G; Abe J; Kohsaka T Eur J Biochem; 1999 Jul; 263(2):326-37. PubMed ID: 10406939 [TBL] [Abstract][Full Text] [Related]
35. The crystal structure of staphylococcal enterotoxin H: implications for binding properties to MHC class II and TcR molecules. Hâkansson M; Petersson K; Nilsson H; Forsberg G; Björk P; Antonsson P; Svensson LA J Mol Biol; 2000 Sep; 302(3):527-37. PubMed ID: 10986116 [TBL] [Abstract][Full Text] [Related]
36. The Yersinia pseudotuberculosis complex: characterization and delineation of a new species, Yersinia wautersii. Savin C; Martin L; Bouchier C; Filali S; Chenau J; Zhou Z; Becher F; Fukushima H; Thomson NR; Scholz HC; Carniel E Int J Med Microbiol; 2014 May; 304(3-4):452-63. PubMed ID: 24598372 [TBL] [Abstract][Full Text] [Related]
37. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Acharya KR; Passalacqua EF; Jones EY; Harlos K; Stuart DI; Brehm RD; Tranter HS Nature; 1994 Jan; 367(6458):94-7. PubMed ID: 8107781 [TBL] [Abstract][Full Text] [Related]
38. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Jardetzky TS; Brown JH; Gorga JC; Stern LJ; Urban RG; Chi YI; Stauffacher C; Strominger JL; Wiley DC Nature; 1994 Apr; 368(6473):711-8. PubMed ID: 8152483 [TBL] [Abstract][Full Text] [Related]
39. Intranasal inoculation of mice with Yersinia pseudotuberculosis causes a lethal lung infection that is dependent on Yersinia outer proteins and PhoP. Fisher ML; Castillo C; Mecsas J Infect Immun; 2007 Jan; 75(1):429-42. PubMed ID: 17074849 [TBL] [Abstract][Full Text] [Related]
40. A novel superantigenic exotoxin from Yersinia psuedotuberculosis and its position in the classification of the entire bacterial toxins. Uchiyama T Contrib Microbiol Immunol; 1995; 13():191-4. PubMed ID: 8833831 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]